ArticleMolecular cancer2025
Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma.
Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NADPH-producing enzymes restrict the formation of pancreatic precancerous lesions.Nature metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundProduction of mitochondrial reactive oxygen species (mROS) induces acinar-to-ductal metaplasia (ADM), an initiating step towards pancreatic ductal adenocarcinoma (PDAC). Manganese superoxide dismutase (SOD2, MnSOD) is the major mitochondrial ROS scavenger and less active SOD2 at the mitochondria increases risk of developing PDAC, indicating clinical relevance of SOD2. However, the role of SOD2 in PDAC tumorigenesis remains elusive.
methodsTo determine SOD2’s role in PDAC initiation and progression, we crossed Sod2fl/fl mice into the p48Cre;LSL-KrasG12D (KC) mouse model. We also utilized mouse primary acinar cells and macrophages for in vitro ADM and ROS assays, and to evaluate initiating events downregulating Sod2. Human expression data and tissue assessed clinical relevance.
resultsSOD2 is downregulated in low-grade lesions, but knockout alone is insufficient for lesion formation. In conjunction with oncogenic Kras, knockout of Sod2 facilitates dysplasia and cancer stem cell formation in the canonical PDAC progression pathway but also increases presence of oxidative stress-resistant atypical flat lesions (AFLs), which are an understudied direct precursor to PDAC.
conclusionsOncogenic Kras suppresses mitohormesis, a process whereby mitochondrial stress upregulates stress-reducing protective responses to enhance cell viability. Inflammatory macrophage signaling decreases Sod2 expression, increasing ROS and promoting ADM and canonical PanIN progression or alternatively, compensatory antioxidants GPX4 and NRF1 are upregulated in atypical flat lesions (AFLs), decreasing senescence and lipid peroxidation. With additional inflammation, increased dysplasia results in accelerated tumor formation and the presence of AFL leads to more poorly-differentiated tumor areas. This is of clinical significance, as poorly-differentiated human PDAC has a lower survival rate, and these tumors show less SOD2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.